GLP-1 Receptor Agonists in Obese Patients with Inflammatory Bowel Disease: from Molecular Mechanisms to Clinical Considerations and Practical Recommendations for Safe and Effective Use.
Konstantinos ArvanitakisTheocharis KoufakisDjordje PopovicGiuseppe MalteseOmar MustafaMichael DoumasOlga GioulemeKalliopi KotsaGeorgios S GermanidisPublished in: Current obesity reports (2023)
Preliminary data suggest that GLP-1 RA can modulate crucial pathways in the pathogenesis of IBD, such as chronic inflammation circuits, intestinal tight junctions, and gut microbiome dysbiosis, setting the stage for human trials to investigate the role of these agents in the treatment of IBD among people with or without diabetes and obesity. However, gastrointestinal side effects related to GLP-1 RA need appropriate clinical management to mitigate risks and maximize the benefits of therapy in people with IBD. GLP-1 RA originally emerged as drugs for the treatment of hyperglycemia and are currently licensed for the management of T2D and/or overweight/obesity. However, their wealth of pleiotropic actions soon raised expectations that they might confer benefits on non-metabolic disorders. Future studies are expected to clarify whether GLP-1 RA deserve an adjunct place in the arsenal of drugs against IBD.
Keyphrases
- weight loss
- rheumatoid arthritis
- type diabetes
- metabolic syndrome
- insulin resistance
- disease activity
- weight gain
- patients with inflammatory bowel disease
- ulcerative colitis
- endothelial cells
- ankylosing spondylitis
- systemic lupus erythematosus
- bariatric surgery
- cardiovascular disease
- combination therapy
- skeletal muscle
- interstitial lung disease
- replacement therapy
- machine learning
- smoking cessation
- body mass index
- single molecule
- induced pluripotent stem cells